Zentalis Pharmaceuticals Inc stock is traded at $1.70, with a volume of 1,299,521. It is up +1.19% in the last 24 hours and down -29.17% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Previous Close:
$1.68
Open:
$1.68
24h Volume:
1,299,521
Relative Volume:
0.89
Market Cap:
$167.05M
Revenue:
$26.87M
Net Income/Loss:
-$124.13M
P/E Ratio:
-
EPS:
-$1.74
Net Cash Flow:
-$125.60M
1W Performance:
-1.16%
1M Performance:
-29.17%
6M Performance:
-60.28%
1Y Performance:
+28.79%
1-Day Range:
$1.63$1.76
1-Week Range:
$1.63$1.98
52-Week Range:
$1.28$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(858) 263-4333Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS